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Abstract Three different accurate, sensitive and reproducible stability-indicating methods for the
determination of pipazethate HCl in the presence of its alkaline degradation product are presented.
The ﬁrst method is based on ratio-spectra 1st derivative (RSD1) spectrophotometry of the drug at
305 nm, over a concentration range of 10–70 lg mL1 with mean percentage recovery of
99.69 ± 1.10. The second method utilises quantitative densitometric evaluation of thin-layer
chromatography of pipazethate HCl in the presence of its alkaline degradation product, using
methanol: ethyl acetate: ammonia (8:2:0.2, v/v/v) as a mobile phase. Chromatograms are scanned
at 251 nm. This method analyses pipazethate HCl in a concentration range of 4–14 lg/spot with
mean percentage recovery of 100.19 ± 0.77. The third method is an HPLC method for the simul-
taneous determination of pipazethate HCl in the presence of its alkaline degradation product. The
mobile phase consists of methanol: ammonium sulphate (1%), pH= 5.7, (80:20, v/v). The standard
curve of pipazethate HCl shows a good linearity over a concentration range of 5–200 lg mL1 with
mean percentage recovery of 100.67 ± 0.91. These methods were successfully applied to the deter-
mination of pipazethate HCl in bulk powder, laboratory-prepared mixtures containing different
percentages of the degradation product and pharmaceutical dosage forms. The validity of results
was assessed by applying standard addition technique. The results obtained were found to agree sta-
tistically with those obtained by a reported method, showing no signiﬁcant difference with respect
to accuracy and precision.
ª 2009 University of Cairo. All rights reserved.
Introduction
Pipazethate HCl is 2-(2-piperidinoethoxy)ethyl 10H-pyrido
[3,2-b] [1,4]benzothiadiazine-10-carboxylate hydrochloride [1],
Fig. 1.
Pipazethate HCl is a non narcotic antitussive drug that acts
by suppressing irritable and spasmodic cough by inhibiting the
excitability of the cough centre and of peripheral neural recep-
tors in the respiratory passage [2,3].
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Several methods have been reported for the analysis of
pipazethate HCl in both pure and pharmaceutical dosage
forms; these include HPLC [4,5], qualitative TLC [6] and elec-
trochemical methods [7,8].
HPLC has been performed by measuring peak area either
at 230 nm using methanol: ammonium sulphate (1%) (85:15,
v/v) as a mobile phase on ion exchange column [4], or at
276 nm using methanol: water (60:40, v/v) as a mobile phase
on C18 column [5].
Spectrophotometric methods, measuring absorption at
251 nm in 0.1 N HCl solution [3,9] and colorimetric proce-
dures with different dyes [10–12], have been described. Spec-
trophotometric methods based on the oxidation of the drug
by Fe3+ in the presence of o-phenanthroline (o-phen) or bipyr-
idyl (bipy); or reduction of Fe(III) by the drug in an acid med-
ium and subsequent interaction of Fe(II) with ferricyanide to
form Prussian blue, which exhibits an absorption maximum
at 750 nm have also been reported [13].
Colorimetric methods, depending upon the reaction of co-
balt(II)-thiocyanate or molybdenum(V)-thiocyanate ions with
the cited drug to form stable ion-pair complexes, have been ci-
ted [14]. Another spectrophotometric method consists of
extracting the formed ion-associates of the drug with chromo-
trope 2B or chromotrope 2R into chloroform and measuring
the produced colours spectrophotometrically [15].
None of these methods is concerned with the analysis of
pipazethate HCl in the presence of its alkaline degradation
product, thus the aim of the present study was to develop sim-
ple and accurate stability-indicating methods for selective
determination of pipazethate HCl in the presence of its alka-
line degradation product with the application to pharmaceuti-
cal dosage forms that could be applied for drug quality
control.
Experimental
Apparatus
All absorption spectra were recorded with a Shimadzu UV-
1601 PC UV–Visible double beam spectrophotometer with
1 cm quartz cuvettes, Shimadzu Corporation, Kyoto-
Japan.
Densitometer: dual wavelength Shimadzu ﬂying CS-9000
with video display and high-speed, high-quality, parallel-
head printer/plotter.
Hamilton micro-syringe, 25 lL or 100 lL, calibrated at
0.2 lL per unit.
Thin-layer chromatography (TLC) plates: pre-coated with
Silica Gel GF254, 20 · 20 cm, 0.25 mm thickness, (E.
Merck, Darmstadt, Germany).
The HPLC system consisted of a Shimadzu LC-10 AD
HPLC pump and a model SPD-10A Shimadzu UV–Visible
detector. The analytical column was a Bondapak C18
(150 mm · 3.9 mm I.D., particle size 5 lm) from Waters,
USA. The detector was operating at 230 nm and the sensi-
tivity was set at 0.001 AUFS. The elution was isocratic with
a ﬂow rate of 0.5 ml min1.
The mobile phase was prepared by mixing methanol with 1%
ammonium sulphate, 80:20 v/v, and the pH was adjusted to 5.7
with either dilute sulphuric acid or ammonia solution.
Materials
Samples
Pure sample. Pipazethate HCl was kindly supplied by Egyptian
International Pharmaceutical Industries Co. (EIPICO), Cairo,
Egypt. Its purity was found to be 100.60 ± 0.61 by a reported
spectrophotometric method [3].
Pharmaceutical dosage forms. Selegon drops are claimed to
contain 40 mg pipazethate HCl per 1 mL. Selegon 20 mg tab-
lets and Selegon 10 mg suppositories (batch numbers 024891,
011047 and 032414, respectively) were purchased from the
local market. All dosage forms were manufactured by
Egyptian International Pharmaceutical Industries Co. (EIPI-
CO), Cairo, Egypt.
Preparation of alkaline degraded sample. The alkaline degrada-
tion product was laboratory prepared by dissolving 100 mg of
pure pipazethate HCl in the least amount of methanol, re-
ﬂuxed with 100 mL 2 M NaOH in a 500-mL ﬂask for 5 h, as
it was proved by TLC to be the time required for complete deg-
radation of the drug. The formed precipitate was ﬁltered,
washed with distilled water (5 · 10 mL), transferred to a ﬂat
bottom dish and dried at 105 C for 2 h. The residue left after
drying was used as the alkaline degradation product of pipaz-
ethate HCl. Structure elucidation was conducted by IR and
mass spectroscopy.
Chemicals
All chemicals and reagents were of pure spectroscopic analyt-
ical grade. 2 M NaOH, 0.1 N HCl, ammonium sulphate
(96%), concentrated ammonia (speciﬁc gravity 0.91), metha-
nol, dichloromethane and ethyl acetate were all obtained from
El-Nasr Pharmaceutical Chemicals Co., Abu Zabaal, Cairo,
Egypt.
De-ionised water and methyl alcohol (E. Merck, Darms-
tadt, Germany) were of HPLC grade.
Standard solutions
Stock solution of pipazethate HCl or its alkaline degradation
product (100 lg mL1) in 0.1N HCl, for ratio-spectra 1st
derivative (RSD1), was prepared by dissolving 100 mg of
pipazethate HCl powder or its alkaline degradation product
in 0.1 N HCl in a 100-mL measuring ﬂask. Ten millilitres of
this solution were accurately transferred into a 100-mL mea-
suring ﬂask and the volume was completed with 0.1 N HCl.
Pipazethate HCl stock standard solution or its alkaline deg-
radation product (1000 lg mL1) in methanol for spectrodensi-
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Figure 1 Chemical structure of pipazethate HCl, C21H25N3O3-
SÆHCl, M.Wt. = 436.
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tometric and HPLC methods, were prepared by accurately
weighing 100 mg of pipazethate HCl powder or its alkaline
degradation product in a 100-mL measuring ﬂask and dissolv-
ing in methanol.
Procedures
Ratio-spectra 1st derivative (RSD1) spectrophotometric method
Construction of calibration curve. Accurately measured volumes
of pipazethate HCl stock solution (100 lg mL1) were trans-
ferred into 10-mL measuring ﬂasks, diluted to volume with
0.1 N HCl to get ﬁnal concentrations 10–70 lg mL1. The
absorption spectra of pipazethate HCl solutions were divided
by the absorption spectra of the alkaline degradation product
(20 lg mL1). The obtained ratio spectra were differentiated
with respect to wavelength, and 1st derivative values at
305 nm were recorded. First derivative values were plotted ver-
sus the corresponding concentration and the regression equa-
tion was calculated. The experiment was repeated three times.
Assay of laboratory-prepared mixtures. Aliquots of pipazethate
HCl stock solution (100 lg mL1) were accurately transferred
into a series of 10-mL measuring ﬂasks to get ﬁnal concentra-
tions of 90%, 80%, (. . .) 30% of pipazethate HCl. Aliquots of
alkaline degradation product stock solution (100 lg mL1)were
added to the same ﬂasks to get ﬁnal concentrations of 10%,
20%, (. . .) 70% of the alkaline degradation product. The vol-
umes were completed with 0.1 N HCl and mixed thoroughly.
The RSD1 values were recorded at 305 nm. The concentration
of pipazethate HCl was calculated from its regression equation.
Each concentration was calculated from four experiments.
Spectrodensitometric method
Construction of calibration curve. Aliquot volumes (0.4,
0.6, . . . 1.4 mL) of pipazethate HCl standard stock solution
(1000 lg mL1) were transferred into a series of 10 mL mea-
suring ﬂasks and diluted to volume with methanol. A sample
of 100 lL was applied to a thin layer chromatographic plate
(20 · 20) using a 25 lL Hamilton syringe. Spots were spaced
2 cm apart from each other and 2 cm from the bottom edge
of the plate. The plate was developed in a chromatographic
tank previously saturated for at least 1 h with the developing
mobile phase; methanol: ethyl acetate: ammonia (8:2:0.2, v/
v/v), by ascending mode. The plate was removed, dried in air
and the spots were visualized under UV lamp at 254 nm and
scanned at 251 nm. The calibration curve was plotted between
the recorded area under the peak and the corresponding con-
centration, from which the regression equation was calculated.
The calibration curve was made from the average of three
experiments.
Assay of laboratory-prepared mixtures. Aliquots of pipazethate
HCl stock solution (1000 lg mL1) were accurately transferred
into a series of 10-mL measuring ﬂasks to get ﬁnal concentra-
tions of 90%, 70%, (. . .) 10% of pipazethate HCl. Accurately
measured volumes of alkaline degradation product stock solu-
tion (1000 lg mL1) were introduced to the same ﬂasks to get
ﬁnal concentrations of 10%, 20%, (. . .) 90% of alkaline degra-
dation product. Hundred microlitres of the prepared mixtures
were applied to a silica gel plate and the procedure under
‘Construction of calibration curve’ was followed. The concen-
trations of pipazethate HCl were calculated from the corre-
sponding regression equation. Four replicates for each
experiment were conducted.
HPLC method
Construction of calibration curve. Accurately measured vol-
umes of pipazethate HCl stock solution (1000 lg mL1) were
transferred into 10-mL measuring ﬂasks, diluted to the volume
with the mobile phase to get the ﬁnal concentration range of 5–
200 lg mL1. Twenty microlitres of these solutions were in-
jected into the HPLC system. The chromatograms were re-
corded and a calibration curve for pipazethate HCl was
plotted and the corresponding regression equation was calcu-
lated. Triplicate experiments were performed.
Assay of laboratory-prepared mixtures. Aliquots of pipazethate
HCl stock solution (1000 lg mL1) were accurately transferred
into a series of 10-mL measuring ﬂasks to get ﬁnal concentra-
tions of 90%, 70%, (. . .) 10% of pipazethate HCl. Portions of
alkaline degradation product stock solution (1000 lg mL1)
were introduced to the same ﬂasks to get ﬁnal concentrations
of 10%, 30%, (. . .) 90% of alkaline degradation product, then
the volume was completed to the mark with the mobile phase.
The chromatographic conditions were adopted for each labo-
ratory-prepared mixture and the concentration of pipazethate
HCl was calculated from the regression equation. Each con-
centration was conducted from four experiments.
System suitability. Twenty microlitres of the solvent mixture
and the working standard solutions were injected. The system
suitability parameters, retention time, tailing factor, theoretical
plate count (N), height of theoretical plate (HETP), separation
of pipazethate HCl peak and its degradation product peak
(resolution) and column capacity were calculated.
Application to pharmaceutical dosage forms
Selegon drops. Accurately measured 2.5 mL selegon drops
(1 mL = 40 mg pipazethate HCl), were transferred into a
100-mL measuring ﬂask and the volume was completed to
the mark with 0.1 N HCl, for RSD1 method, or with metha-
nol, for densitometric and HPLC methods (1000 lg mL1).
Ten millilitres of this drop solution (1000 lg mL1) was trans-
ferred into a 100 mL measuring ﬂask and diluted to the mark
with 0.1 N HCl to get a ﬁnal concentration of 100 lg mL1,
then the procedures under ‘Construction of calibration curves’
for each method were followed. Four replicates for each exper-
iment were done.
Selegon tablets. Twenty selegon tablets were weighed and pow-
dered. A portion of the powder equivalent to 100 mg pipaze-
thate HCl was accurately weighed into a 100 mL beaker,
stirred with 0.1 N HCl, for RSD1 method, or with methanol,
for densitometric and HPLC methods (4 · 20 mL) and ﬁltered
into a 100-mL measuring ﬂask. The volume was completed
with the same solvent (1000 lg mL1). Ten millilitres of this
tablet stock solution (1000 lg mL1) was transferred into a
100 mL measuring ﬂask and diluted to the mark with 0.1 N
HCl to get a ﬁnal concentration of 100 lg mL1, then the pro-
cedures under ‘Construction of calibration curves’ for each
method were followed. Each concentration was done from
four experiments.
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Selegon suppositories. Twenty selegon suppositories were
melted and mixed well. A quantity containing 100 mg of pipaz-
ethate HCl was weighed and accurately transferred into a
100 mL beaker, extracted by shaking with 0.1 N HCl, for
RSD1 method, or with methanol, for densitometric and HPLC
methods (4 · 20 ml) and decanted through ﬁlter paper into a
100-mL measuring ﬂask. The volume was completed with the
same solvent (1000 lg mL1). 10 mL of this suppository stock
solution (1000 lg mL1) was transferred into 100 mL measur-
ing ﬂask and diluted to the mark with 0.1 N HCl to get a ﬁnal
concentration of 100 lg mL1, then the procedures under
‘Construction of calibration curves’ for each method were per-
formed. Four replicates for each experiment were done.
Results and discussion
Many pharmaceutical compounds undergo degradation dur-
ing storage or even during the different processes of their man-
ufacture. Several chemical or physical factors can lead to the
degradation of drugs [16]. Hydrolysis and oxidation are the
most famous chemical degradation routes of drugs [17,18].
The main classes of drugs that are subject to degradation are
esters, amides and lactams. Ester hydrolysis is frequently base
catalysed, which makes the reaction rapid and irreversible
[17,19].
Pipazethate HCl has an ester linkage, so trials were con-
ducted for its degradation in either an acidic or basic med-
ium. It was found that the drug was liable to degradation
upon reﬂuxing in a strong basic medium to give two degra-
dates. One is the alcohol derived from the hydrolysis of the
ester group of the drug. This alcohol has no absorption at
251 nm, as it has no chromophoric group, thus it does not
interfere with the determination of the intact drug. The other
is the free base which remains after decarboxylation under
the conditions of the reaction demonstrated in the following
scheme (Scheme 1).
In this work, alkali-hydrolysed pipazethate HCl degrada-
tion product was prepared, separated and its structure identi-
ﬁed by mass spectroscopy. It shows the parent peak at 201
m/z while the peak of pipazethate HCl is at 398 m/z. This indi-
cates that the ester group suffered cleavage by 2 M NaOH
leading to the formation of the corresponding base (after
decarboxylation). This was further conﬁrmed by IR spectros-
copy. IR spectroscopy of the degradation product showed
the disappearance of the carbonyl band at 1750 cm1.
The present work was conducted for the selective determina-
tion of pipazethate HCl in the presence of its alkali-hydrolysed
degradation product with the application to pharmaceutical
dosage forms.
Ratio-spectra 1st derivative (RSD1) spectrophotometric method
Ratio-spectra 1st derivative spectrophotometry (RSD1) is an
analytical technique of good utility which offers background
correction and better selectivity than normal spectrophotome-
try for resolving binary mixtures and some ternary mixtures
[20].
The zero-order absorption spectra of pipazethate HCl and
its degradation product showed severe overlap over the entire
spectrum of the intact drug, Fig. 2. Therefore, the use of direct
absorbance measurements for assaying pipazethate HCl in the
presence of its degradation product was not possible.
The 1st, 2nd, 3rd and 4th order absorption spectra of pipaz-
ethate HCl in the presence of its alkaline degradation product
showed severe spectral overlap with no zero crossing points.
Therefore ratio-spectra 1st derivative (RSD1) method was sug-
gested to solve this problem.
The theory of derivative ratio spectrophotometry, which is
based on the use of ﬁrst (or second) derivatives of the ratio
spectra of the mixture and divided (amplitudes at each wave-
length) by the absorption spectrum of a standard solution of
one of the components, has been applied extensively to the
simultaneous determination of substances with overlapping
spectra as an economic alternative to HPLC methods [21],
and to solve the problem of overlapping absorption spectra
of pipazethate HCl and its alkaline degradation product. In
the present investigation, the careful choice of the divisor
and the working wavelength were of great importance as it af-
fected both sensitivity and selectivity; accordingly, different
concentrations of the degradation product (10, 20, 30 and
60 lg mL1) were tried as divisors. It was found that
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Scheme 1
Figure 2 Absorption spectra of 50 lg mL1 pipazethate HCl (–)
and 20 lg mL1 of its alkaline degradation product (. . .).
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20 lg mL1 was the best, as it produced minimum noise and
gave better results in agreement with selectivity.
Pipazethate HCl was assayed by dividing the absorption
spectra of different concentrations in the range of 10–
70 lg mL1 by the absorption spectra of 20 lg mL1 alkaline
degradation product, Fig. 3. The obtained ratio spectra were
differentiated with respect to wavelength, Fig. 4. The RSD1
values showed good linearity and accuracy. The regression
equation was computed to be:
Y ¼ 0:211X 0:0021 r ¼ 0:9998;
where Y is the RSD1 value at 305 nm, X is the concentration in
lg mL1 and r is the correlation coefﬁcient.
Determination of pipazethate HCl in the presence of its
alkaline degradation product could also be performed by
RSD1 at 273 nm. This wavelength showed good linearity and
accuracy, but less than at 305 nm.
Results obtained in Table 1 show that the proposed method
is valid and applicable for simultaneous determination of
pipazethate HCl in the presence of up to 70% of the alkaline
degradation product in different laboratory-prepared mixtures
with mean percentage recovery 99.38 ± 0.82.
Spectrodensitometric method
TLC densitometry overcomes the problem of overlapping
absorption spectra of a mixture of drugs by separating these
components on TLC plates and determining each ingredient
by scanning the corresponding chromatogram. The TLC–UV
densitometric method has the advantage of simultaneously
determining the active ingredients in multi-component dosage
forms [22].
The proposed procedure is based on the difference in Rf val-
ues of pipazethate HCl (Rf = 0.28) and its alkaline degrada-
tion product (Rf = 0.51). Various developing systems were
tried, but complete separation was achieved using methanol:
ethyl acetate: ammonia (8:2:0.2, v/v/v).
The separated spots from different concentrations of the
drug were scanned at 251 nm. A linear relation was obtained
between peak area and concentration in the range of 4–
14 lg/spot, from which the linear regression equation was
found to be:
Y ¼ 0:1053Xþ 0:2469 r ¼ 0:9995;
where Y is the area under the peak, X is the concentration in
lg/spot and r is the correlation coefﬁcient.
The results obtained during analysis of laboratory-prepared
mixtures, Table 2, show that the method is valid for the
Figure 4 First derivative ratio spectra of pipazethate HCl (10–
70 lg mL1) using 20 lg mL1 of its alkaline degradation product
as a divisor.
Table 1 Determination of pipazethate HCl in laboratory-
prepared mixtures by the proposed RSD1 method.
Mixture no. Alkaline
degradate
added%
Pipazethate HCl
Taken
(lg mL1)
Founda
(lg mL1)
Recovery
(%)
1 10.00 63.00 62.47 99.16
2 20.00 56.00 55.98 99.96
3 25.00 52.50 52.09 99.22
4 30.00 49.00 48.11 98.18
5 40.00 42.00 42.04 100.10
6 50.00 35.00 34.60 98.86
7 60.00 28.00 28.20 100.70
8 70.00 21.00 20.76 98.87
Mean ± SD 99.38 ± 0.82
a Average of four determinations.
Table 2 Determination of pipazethate HCl in laboratory-
prepared mixtures by the suggested TLC densitometric method.
Mixture no. Alkaline
degradate
added (%)
Pipazethate HCl
Taken
(lg mL1)
Founda
(lg mL1)
Recovery
(%)
1 10.00 12.60 12.59 99.99
2 20.00 11.20 11.28 100.71
3 40.00 8.40 8.36 99.52
4 60.00 5.60 5.62 100.36
5 70.00 4.20 4.22 100.48
Mean ± SD 100.21 ± 0.47
a Average of four determinations.
Figure 3 Ratio spectrum of 50 lg mL1 pipazethate HCl using
20 lg mL1 of its alkaline degradation product as a divisor.
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determination of intact pipazethate HCl in the presence of its
alkaline degradation product up to 90% alkaline degradation
product in different laboratory-prepared mixtures with mean
percentage recovery of 100.21 ± 0.47.
HPLC method
A simple HPLC method was adopted for the simultaneous
determination of pipazethate HCl in the presence of its alka-
line degradation product without pervious separation.
Different mobile systems were tried, methanol: acetate buf-
fer with different ratios and pH or with ammonium sulphate,
for the chromatographic separation of the drug from its alka-
line degradation product. The best resolution was achieved
when using a mobile phase consisting of methanol: 1% ammo-
nium sulphate (pH = 5.73) (80:20, v/v) using UV detection at
230 nm, which gave a better sensitivity for both drug and its
alkaline degradation product.
A linear relation was obtained between peak area and the
concentration of pipazethate HCl in the range of 5–
200 lg mL1. The linear regression equation was found to be:
Y ¼ 0:10057Xþ 0:2723 r ¼ 0:9999;
where Y is the area under the peak, X is the concentration in
lg mL1 and r is the correlation coefﬁcient.
Results obtained by applying the HPLC procedure showed
that pipazethate HCl can be simultaneously analysed in the
presence of its alkaline degradation product in the labora-
tory-prepared mixtures, Table 5. The method is valid for the
determination of intact pipazethate HCl in the presence of
up to 90% alkaline degradation product, which was consid-
ered as the maximum expected degradation product to be
available in a sample product in different laboratory-prepared
mixtures with mean percentage recovery of 100.95 ± 0.33;
Table 3.
The proposed methods have been applied to assay pipaze-
thate HCl in selegon drops, tablets and suppositories. The
validity of the suggested procedures was further assessed by
applying the standard addition method, Table 4.
System suitability tests, which are used to ensure system
performance before or during the analysis of drugs, were per-
formed. The obtained values of pipazethate HCl and its alka-
Table 3 Determination of pipazethate HCl in laboratory-
prepared mixtures by the elaborated HPLC method.
Mixture no. Alkaline
degradate
added (%)
Pipazethate HCl
Taken
(lg mL1)
Founda
(lg mL1)
Recovery
(%)
1 10.00 180.00 181.01 100.56
2 30.00 140.00 141.01 100.72
3 50.00 100.00 100.97 100.97
4 70.00 60.00 60.66 101.10
5 90.00 20.00 20.28 101.40
Mean ± SD 100.95 ± 0.33
a Average of four determinations.
Table 4 Application of standard addition technique for the analysis of pipazethate HCl in its pharmaceutical dosage forms by the
proposed RSD1, TLC densitometric and HPLC methods.
Product Method Founda (%) Recovery (%)
Selegon drops B. N. 024891 RSD1 99.39 ± 0.92 100.16 ± 0.75
Selegon tablets B. N. 011047 99.36 ± 0.59 99.60 ± 1.17
Selegon suppositories B. N. 032414 99.92 ± 1.01 100.64 ± 0.85
Selegon drops B. N. 024851 TLC 100.30 ± 0.23 100.23 ± 0.23
Selegon tablets B. N. 025149 100.29 ± 0.37 100.00 ± 0.59
Selegon suppositories B. N. 042720 99.08 ± 0.97 99.67 ± 0.32
Selegon drops B.N. 032368 HPLC 101.54 ± 0.62 101.42 ± 0.54
Selegon tablets B.N. 011047 99.69 ± 0.84 100.98 ± 0.72
Selegon suppositories B.N. 0321414 99.39 ± 1.01 99.38 ± 0.46
a Average of four determinations.
Table 5 System suitability parameters of the elaborated HPLC method for the analysis of pipazethate HCl in the presence of its
alkaline degradation product.
Parameter Obtained value Reference value [23]
Resolution (R) 1.04 R> 0.8
T (tailing factor) 1 T= 1 for a typical symmetric peak
Relative retention time 1.94 >1
K (column capacity) Pipazethate HCl (1.27) alkaline degradate (3.42) 1–10 acceptable
N (column eﬃciency) Pipazethate HCl (483.2) alkaline degradate (1393.4) Increases with eﬃciency of the separation
HETP (height equivalent
to theoretical plates)
Pipazethate HCl (.0668) alkaline degradate (.0099) The smaller the value. The higher the column eﬃciency
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line degradation product were agreed with the stated reference
values [23], Table 5.
A statistical comparison of the results obtained by the pro-
posed methods and a reported method [3] for pure drug is
shown in Table 6. The values of the calculated t and F were less
than the corresponding tabulated ones, which revealed that
there was no signiﬁcant differences with respect to accuracy
and precision between the proposed methods and the reported
procedure.
Assay validation was done by repeating the procedures
three times on three different days (inter-day) and three times
on different times intervals within the same day (intraday) for
the analysis of different concentrations of pipazethate HCl,
Table 7. The results show that the methods were accurate, pre-
cise and speciﬁc.
The robustness of the methods and their ability to remain
unaffected by small changes in parameters were tested. Varia-
tion of pH of the mobile phase by ±0.2 and its organic solvent
concentration by 4% did not have a signiﬁcant effect on chro-
matographic resolution of the HPLC method. Variation of the
concentration of HCl by ±0.02 M did not have signiﬁcant ef-
fect on spectrophotometric methods.
Conclusion
Three methods, RSD1, TLC and HPLC were developed for the
determination of pipazethate HCl in the presence of its alka-
line degradation product. The methods provide simple, accu-
rate, rapid and reproducible quantitative analysis of
pipazethate HCl in bulk powder, laboratory-prepared mix-
tures and dosage forms.
The RSD1 method has the advantages of being more eco-
nomical, rapid and environmentally secure than the other
methods. The TLC method was found to be more sensitive
than the RSD1 method. The proposed HPLC method gives a
good resolution between pipazethate HCl and its alkaline deg-
radation products within a short time and a dynamic range.
These methods can be used as stability-indicating procedures
in quality control laboratories where economy and time are
essential.
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